Looks like the catalyst is in with this quarter report. A terrible report. -6% the stock. They don't have money to bring a drug to market in 2016 17?, lawyer fees etc etc. Either they do another dilution, the problem there is not much to dilute, or they get acquired on the cheap. Management painted this once great company into a corner.